St.Jude is clearly keen to grab some land in the TAVI market, announcing the first patient implant of its 23 mm Portico™ Transcatheter Aortic Heart Valve using the Transapical Delivery System..
Last week we covered the CE marking of St.Jude’s offering in the pursuit of a place in the transcatheter aortic valve implantation (TAVI) market alongside Edwards Lifesciences and Medtronic. Portico is designed to be able to be inserted either via the femoral artery or transapically. It’s unique feature is its re-sheathability which the company says increases physicians’ control and placement accuracy during valve deployment and also allows the physician to retrieve the valve, if necessary.
“The Portico heart valve offers additional options in terms of resheathing, retrieving or repositioning the valve which in turn facilitates more accurate placement,” said Dr. Cheung. “The ability to implant a heart valve via the transapical approach provides an important alternative to treat patients who are considered high risk for conventional open-heart surgery.”
“St. Jude Medical incorporates more than 35 years of heart valve experience into the design of the Portico valve and Transapical Delivery System,” said Frank J. Callaghan, president of the St. Jude Medical Cardiovascular and Ablation Technologies Division. “The first patient implanted with the transapical delivery approach represents a significant milestone in our ongoing efforts to provide physicians a wide range of options to best treat their patients.”
As recently as last week, St. Jude Medical announced the CE Mark approval of its 23 mm Portico Transcatheter Aortic Heart Valve and Transfemoral Delivery System. The devices are not yet approved for use in the United States.
Source: St. Jude Medical, Inc.